EICHORCondition: Thymoma · Thymic Carcinoma · Clinical Masaoka Stage II to IVA · Sponsor: Memorial Sloan Kettering Cancer Center
The main purpose of this study is to find out the good and the bad effects that the combination of cetuximab with the traditional chemotherapy regimen of cisplatin, doxorubicin, and cyclophosphamide has when given to patients with later stage thymoma or thymic carcinoma before surgery. The physicians will also look at changes in genes in the tumor that may relate to the effectiveness of cetuximab
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| City of Hope Medical Center | Duarte, California, United States | — |
| Memorial Sloan Kettering at Basking Ridge | Basking Ridge, New Jersey, United States | — |
| Memorial Sloan Kettering Cancer Center @ Suffolk | Commack, New York, United States | — |
| Memorial Sloan Kettering West Harrison | Harrison, New York, United States | — |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | — |
| Memorial Sloan Kettering at Mercy Medical Center | Rockville Centre, New York, United States | — |
| Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center | Sleepy Hollow, New York, United States | — |
| Md Anderson Cancer Center | Houston, Texas, United States | — |
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01025089